

## Correspondence

# Neurological Complic

Br Med J 1958; 2 doi: <https://doi.org/10.1136/>

- [Article](#)
- [Related content](#)
- [Metrics](#)
- [Responses](#)
- [Peer review](#)
- 

AUG. 9, 1958

CORI

## Correspondence

Because of heavy pressure on our space, correspondent asked to keep their letters short.

### Tabo-paresis

SIR.—Some senior and experienced psychiatrists have recently had cause to give considerable thought to the problem of tabo-paresis. One British psychiatrist recently felt that there was concern in responsible circles in America on the same topic. When the time-lag between primary infection with syphilis and the onset of tabo-paresis is considered it appears possible that the recent virtual disappearance of tabo-paresis is due to the efficiency of arsenical treatment in the years before the large-scale employment of antibiotics.

It may be that cases treated in the early years of the antibiotic era have yet to develop tabo-paresis. The factor suggests that the next few years may be particularly important in this respect. Recently a senior psychiatrist with considerable experience of neurosyphilis had cases referred to him within a very short period—more than he had seen for a very long time previously. In these cases could easily have been missed by a more junior man with little practical experience of tabo-paresis. However, some of the old, characteristic physical signs seem to be changing somewhat.

It may be hoped that fears of a reappearance of tabo-paresis on a considerable scale may prove groundless, but there appears to be reason for clinicians to be very alert on this topic, so that if an increase in the number of cases

Royal Medico-Psychological Association.

### Neurological Complications of Pertussis Immunization

SIR.—Drs. D. C. Thursby-Pelham and C. Giles's letter (*Journal*, July 26, p. 246) is of great interest. It is remarkable that Dr. Thursby-Pelham has seen six patients in the space of 10 years with neurological reactions following pertussis immunization, in view of the fact that only seven such cases have been recorded in Great Britain (see my paper, *Journal*, July 5, p. 24). One of these seven is Case 2 in their series. It may be, as Drs. Thursby-Pelham and Giles state, that the dangers of whooping-cough immunization are greater than is commonly thought, but this can only be established if the possibility of reactions to immunization are borne in mind and reported when they occur. One would like to make a plea, therefore, that this should be done.

It is possible that the relatively large number of cases of neurological complications of pertussis immunization reported from the United States, as opposed to other countries, including Britain, is due to a greater awareness of, and interest in, the problem in America. If further cases are reported, as Drs. Thursby-Pelham and Giles have now done, it may be that the commonly held view, that the dangers from whooping-cough itself are much greater than those from immunizing against it, will require modification.—I am, etc.,

London, S.W.17.

J. M. BERG.

SIR.—Further to the article by Dr. J. M. Berg (*Journal*, July 5, p. 24) and the letter from Dr. D. C. Thursby-Pelham and Dr. C. Giles (*Journal*, July 26, p. 246), I have given many thousands of injections of both combined diphtheria-pertussis and triple antigen vaccines, and in two instances only have I known convulsions to follow, in sisters.

*Case No. 1.*—A female infant, first child of a Rhesus-negative mother. Became jaundiced three days after birth. Was admitted to hospital but replacement transfusion unnecessary. At 6 months of age she had a severe convulsion which occurred four hours after her first injection of triple antigen. She was un-

for a doctor prescribing dummy tablets, when he has to choose between honesty with his patient and impersonal science; and concludes "regretfully, that it would be wrong for the B.N.F. to include a dummy tablet. . . ." May I set out in detail some of the considerations which should guide a family doctor in his choice of controls for any therapeutic

on those who seek his advice about their treatment. Logically a doctor could only advise a patient to take such an unknown substance if there was no accredited or orthodox treatment for the condition from which he was suffering. The medicaments prescribed by a general practitioner should be those which he uses in good faith and on the basis of knowledge which he has obtained of their composition and action from different sources. Where the progress of a disease invariably follows a predictable and well-established course, then the past experience of accumulated medical knowledge supplies the control for any therapeutic trial of a possibly beneficial drug, and no other may be needed. The most obvious examples are those diseases in which death is the invariable or predictable result. If, on the grounds of a reasonable hypothesis, the first therapeutic trial of a new substance for the treatment of such a disease were being planned—for example, streptomycin in tuberculous meningitis—it could be argued that it would be unethical to withhold this test substance from any patient in the trial. A proper structure of this first trial might well be to test the action of the new substance in a continuous series of cases until the question was beyond doubt, either that it had no action or that the predictable course of the disease was undoubtedly altered by the use of the test substance. In general practice, however, such trials are rare.

Therapeutic research in general practice falls broadly into six categories. The first, and perhaps a neglected field, is a fresh assessment of the action of time-honoured remedies in common diseases—for example, the use of potassium iodide or tincture of stramonium in asthma. Second comes the controlled trial of new drugs for old and familiar diseases, such as the prophylactic use of sulphonamides for the complications of measles. Third come trials designed to reveal new uses of familiar drugs, such as aspirin in diabetes. Fourth, and we hope rarely in general practice, comes the administration of new and unfamiliar drugs to patients with diseases for which a standard treatment already exists. The fifth comprises those trials where the family doctor is in ignorance of the precise nature of the

We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and analytics partners. Our privacy and cookie policy [Show Vendors](#)

[Cookie Settings](#)

[Accept Cookies](#)

cases have been recorded in Great Britain (see my paper, *Journal*, July 5, p. 24). One of these seven is Case 2 in series. It may be, as Drs. Thursby-Pelham and Giles that the dangers of whooping-cough immunization greater than is commonly thought, but this can be established if the possibility of reactions to immunization borne in mind and reported when they occur. One I like to make a plea, therefore, that this should be done.

It is possible that the relatively large number of neurological complications of pertussis immunization reported from the United States, as opposed to other countries including Britain, is due to a greater awareness of, or interest in, the problem in America. If further cases are reported, as Drs. Thursby-Pelham and Giles have now it may be that the commonly held view, that the danger from whooping-cough itself are much greater than from immunizing against it, will require modification.—*etc.*,

London, S.W.17.

J. M. BERG.

SIR.—Further to the article by Dr. J. M. Berg (*Journal*, July 5, p. 24) and the letter from Dr. D. C. Thursby-Pelham and Dr. C. Giles (*Journal*, July 26, p. 246), I have given many thousands of injections of both combined diphtheria-pertussis and triple antigen vaccines, and in two instances only have I known convulsions to follow, in sisters.

*Case No. 1.*—A female infant, first child of a Rhesus-negative mother. Became jaundiced three days after birth. Was admitted to hospital but replacement transfusion unnecessary. At 6 months of age she had a severe convulsion which occurred hours after her first injection of triple antigen. She was un-

usually follows a predictable and well-established course

Royal Medico-Psychological Association.

### Neurological Complications of Pertussis Immunization

SIR.—Drs. D. C. Thursby-Pelham and C. Giles's letter (*Journal*, July 26, p. 246) is of great interest. It is remarkable that Dr. Thursby-Pelham has seen six patients in the space of 10 years with neurological reactions following pertussis immunization, in view of the fact that only seven such cases have been recorded in Great Britain (see my paper, *Journal*, July 5, p. 24). One of these seven is Case 2 in their series. It may be, as Drs. Thursby-Pelham and Giles state, that the dangers of whooping-cough immunization are greater than is commonly thought, but this can only be established if the possibility of reactions to immunization are borne in mind and reported when they occur. One would like to make a plea, therefore, that this should be done.

It is possible that the relatively large number of cases of neurological complications of pertussis immunization reported from the United States, as opposed to other countries, including Britain, is due to a greater awareness of, and interest in, the problem in America. If further cases are reported, as Drs. Thursby-Pelham and Giles have now done, it may be that the commonly held view, that the dangers from whooping-cough itself are much greater than those from immunizing against it, will require modification.—I am, *etc.*,

London, S.W.17.

J. M. BERG.

SIR.—Further to the article by Dr. J. M. Berg (*Journal*, July 5, p. 24) and the letter from Dr. D. C. Thursby-Pelham and Dr. C. Giles (*Journal*, July 26, p. 246), I have given many thousands of injections of both combined diphtheria-pertussis and triple antigen vaccines, and in two instances only have I known convulsions to follow, in sisters.

*Case No. 1.*—A female infant, first child of a Rhesus-negative mother. Became jaundiced three days after birth. Was admitted to hospital but replacement transfusion unnecessary. At 6 months of age she had a severe convulsion which occurred four hours after her first injection of triple antigen. She was un-

on those who seek his advice about their treatment. Logically a doctor could only advise a patient to take such an unknown substance if there was no accredited or orthodox treatment for the condition from which he was suffering. The medicaments prescribed by a general practitioner should be those which he uses in good faith and on the basis of knowledge which he has obtained of their composition and action from different sources. Where the progress of a disease invariably follows a predictable and well-established course, then the past experience of accumulated medical knowledge supplies the control for any therapeutic trial of a possibly beneficial drug, and no other may be needed. The most obvious examples are those diseases in which death is the invariable or predictable result. If, on the grounds of a reasonable hypothesis, the first therapeutic trial of a new substance for the treatment of such a disease were being planned—for example, streptomycin in tuberculous meningitis—it could be argued that it would be unethical to withhold this test substance from any patient in the trial. A proper structure of this first trial might well be to test the action of the new substance in a continuous series of cases until the question was beyond doubt, either that it had no action or that the predictable course of the disease was undoubtedly altered by the use of the test substance. In general practice, however, such trials are rare.

Therapeutic research in general practice falls broadly into six categories. The first, and perhaps a neglected field, is a fresh assessment of the action of time-honoured remedies in common diseases—for example, the use of potassium iodide or tincture of stramonium in asthma. Second comes the controlled trial of new drugs for old and familiar diseases, such as the prophylactic use of sulphonamides for the complications of measles. Third come trials designed to reveal new uses of familiar drugs, such as aspirin in diabetes. Fourth, and we hope rarely in general practice, comes the administration of new and unfamiliar drugs to patients with diseases for which a standard treatment already exists. The fifth comprises those trials where the family doctor is in ignorance of the precise nature of the

This is a PDF-only article. The first page of the

## Log in

## Log in using your username and

[BMA Member Log In](#)

If you have a subscription to The BMJ, log in:

Username \*

Password \*

[Forgot your login details?](#)

We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and analytics partners.

[Our privacy and cookie policy](#) [Show Vendors](#)

[Cookie Settings](#)

[Accept Cookies](#)



Log in through your institution

Subscribe from £138 \*

Subscribe and get access to all BMJ articles,

[Subscribe](#)

\* For online subscription

Access this article for 1 day for:

£30 / \$37 / €33 (plus VAT)

You can download a PDF version for your per

[Buy this article](#)

Like 0

## Article tools

[PDF](#) 0 responses

- [Respond to this article](#)
- [Alerts & updates](#)

### Article alerts

We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and analytics partners.

[Our privacy and cookie policy](#) [Show Vendors](#)

Royal Medico-Psychological Association.

#### Neurological Complications of Pertussis Immunization

SIR,—Drs. D. C. Thursby-Pelham and C. Giles's letter (*Journal*, July 26, p. 246) is of great interest. It is remarkable that Dr. Thursby-Pelham has seen six patients in the space of 10 years with neurological reactions following pertussis immunization, in view of the fact that only seven such cases have been recorded in Great Britain (see my paper, *Journal*, July 5, p. 24). One of these seven is Case 2 in their series. It may be, as Drs. Thursby-Pelham and Giles state, that the dangers of whooping-cough immunization are greater than is commonly thought, but this can only be established if the possibility of reactions to immunization are borne in mind and reported when they occur. One would like to make a plea, therefore, that this should be done.

It is possible that the relatively large number of cases of neurological complications of pertussis immunization reported from the United States, as opposed to other countries, including Britain, is due to a greater awareness of, and interest in, the problem in America. If further cases are reported, as Drs. Thursby-Pelham and Giles have now done, it may be that the commonly held view, that the dangers from whooping-cough itself are much greater than those from immunizing against it, will require modification.—I am, etc.,

London, S.W.17.

J. M. BERG.

SIR,—Further to the article by Dr. J. M. Berg (*Journal*, July 5, p. 24) and the letter from Dr. D. C. Thursby-Pelham and Dr. C. Giles (*Journal*, July 26, p. 246), I have given many thousands of injections of both combined diphtheria-pertussis and triple antigen vaccines, and in two instances only have I known convulsions to follow, in sisters.

*Case No. 1.*—A female infant, first child of a Rhesus-negative mother. Became jaundiced three days after birth. Was admitted to hospital but replacement transfusion unnecessary. At 6 months of age she had a severe convulsion which occurred four hours after her first injection of triple antigen. She was un-

on those who seek his advice about their treatment. Logically a doctor could only advise a patient to take such an unknown substance if there was no accredited or orthodox treatment for the condition from which he was suffering. The medicaments prescribed by a general practitioner should be those which he uses in good faith and on the basis of knowledge which he has obtained of their composition and action from different sources. Where the progress of a disease invariably follows a predictable and well-established course, then the past experience of accumulated medical knowledge supplies the control for any therapeutic trial of a possibly beneficial drug, and no other may be needed. The most obvious examples are those diseases in which death is the invariable or predictable result. If, on the grounds of a reasonable hypothesis, the first therapeutic trial of a new substance for the treatment of such a disease were being planned—for example, streptomycin in tuberculous meningitis—it could be argued that it would be unethical to withhold this test substance from any patient in the trial. A proper structure of this first trial might well be to test the action of the new substance in a continuous series of cases until the question was beyond doubt, either that it had no action or that the predictable course of the disease was undoubtedly altered by the use of the test substance. In general practice, however, such trials are rare.

Therapeutic research in general practice falls broadly into six categories. The first, and perhaps a neglected field, is a fresh assessment of the action of time-honoured remedies in common diseases—for example, the use of potassium iodide or tincture of stramonium in asthma. Second comes the controlled trial of new drugs for old and familiar diseases, such as the prophylactic use of sulphonamides for the complications of measles. Third come trials designed to reveal new uses of familiar drugs, such as aspirin in diabetes. Fourth, and we hope rarely in general practice, comes the administration of new and unfamiliar drugs to patients with diseases for which a standard treatment already exists. The fifth comprises those trials where the family doctor is in ignorance of the precise nature of the



[Cookie Settings](#)

[Accept Cookies](#)

Password \*

Log in

[Register for alerts](#)

-  If you have registered for alerts, you
-  [Citation tools](#)


## Download this article to citatio

Berg J. M.. Neurological Complications

- BibTeX (win & mac)
- EndNote (tagged)
- EndNote 8 (xml)
- RefWorks Tagged (win & mac)
- RIS (win only)
- Medlars

## Help

If you are unable to import citations, ple

- [EndNote](#)
- [ProCite](#)
- [Reference Manager](#)
- [RefWorks](#)
- [Zotero](#)
- [Request permissions](#)
-  [Author citation](#)
- [Articles by J. M. Berg](#)
- [Add article to BMJ Portfolio](#)

[Email to a friend](#)

We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and analytics partners. Our privacy and cookie policy [Show Vendors](#)

Royal Medico-Psychological Association.

### Neurological Complications of Pertussis Immunization

SIR.—Drs. D. C. Thursby-Pelham and C. Giles's letter (*Journal*, July 26, p. 246) is of great interest. It is remarkable that Dr. Thursby-Pelham has seen six patients in the space of 10 years with neurological reactions following pertussis immunization, in view of the fact that only seven such cases have been recorded in Great Britain (see my paper, *Journal*, July 5, p. 24). One of these seven is Case 2 in their series. It may be, as Drs. Thursby-Pelham and Giles state, that the dangers of whooping-cough immunization are greater than is commonly thought, but this can only be established if the possibility of reactions to immunization are borne in mind and reported when they occur. One would like to make a plea, therefore, that this should be done.

It is possible that the relatively large number of cases of neurological complications of pertussis immunization reported from the United States, as opposed to other countries, including Britain, is due to a greater awareness of, and interest in, the problem in America. If further cases are reported, as Drs. Thursby-Pelham and Giles have now done, it may be that the commonly held view, that the dangers from whooping-cough itself are much greater than those from immunizing against it, will require modification.—I am, etc.,

London, S.W.17.

J. M. BERG.

SIR.—Further to the article by Dr. J. M. Berg (*Journal*, July 5, p. 24) and the letter from Dr. D. C. Thursby-Pelham and Dr. C. Giles (*Journal*, July 26, p. 246), I have given many thousands of injections of both combined diphtheria-pertussis and triple antigen vaccines, and in two instances only have I known convulsions to follow, in sisters.

*Case No. 1.*—A female infant, first child of a Rhesus-negative mother. Became jaundiced three days after birth. Was admitted to hospital but replacement transfusion unnecessary. At 6 months of age she had a severe convulsion which occurred four hours after her first injection of triple antigen. She was un-

on those who seek his advice about their treatment. Logically a doctor could only advise a patient to take such an unknown substance if there was no accredited or orthodox treatment for the condition from which he was suffering. The medicaments prescribed by a general practitioner should be those which he uses in good faith and on the basis of knowledge which he has obtained of their composition and action from different sources. Where the progress of a disease invariably follows a predictable and well-established course, then the past experience of accumulated medical knowledge supplies the control for any therapeutic trial of a possibly beneficial drug, and no other may be needed. The most obvious examples are those diseases in which death is the invariable or predictable result. If, on the grounds of a reasonable hypothesis, the first therapeutic trial of a new substance for the treatment of such a disease were being planned—for example, streptomycin in tuberculous meningitis—it could be argued that it would be unethical to withhold this test substance from any patient in the trial. A proper structure of this first trial might well be to test the action of the new substance in a continuous series of cases until the question was beyond doubt, either that it had no action or that the predictable course of the disease was undoubtedly altered by the use of the test substance. In general practice, however, such trials are rare.

Therapeutic research in general practice falls broadly into six categories. The first, and perhaps a neglected field, is a fresh assessment of the action of time-honoured remedies in common diseases—for example, the use of potassium iodide or tincture of stramonium in asthma. Second comes the controlled trial of new drugs for old and familiar diseases, such as the prophylactic use of sulphonamides for the complications of measles. Third come trials designed to reveal new uses of familiar drugs, such as aspirin in diabetes. Fourth, and we hope rarely in general practice, comes the administration of new and unfamiliar drugs to patients with diseases for which a standard treatment already exists. The fifth comprises those trials where the family doctor is in ignorance of the precise nature of the

[Cookie Settings](#)

[✓ Accept Cookies](#)



NOTE: We only request your email address so we can send you relevant information and not junk mail. We do not capture any email address

Username \*

Your Email \*

Send To \*

You are going to email the following [Neurolog](#)  
Your Personal Message

Royal Medico-Psychological Association.

### Neurological Complications of Pertussis Immunization

SIR,—Drs. D. C. Thursby-Pelham and C. Giles's letter (*Journal*, July 26, p. 246) is of great interest. It is remarkable that Dr. Thursby-Pelham has seen six patients in the space of 10 years with neurological reactions following pertussis immunization, in view of the fact that only seven such cases have been recorded in Great Britain (see my paper, *Journal*, July 5, p. 24). One of these seven is Case 2 in their series. It may be, as Drs. Thursby-Pelham and Giles state, that the dangers of whooping-cough immunization are greater than is commonly thought, but this can only be established if the possibility of reactions to immunization are borne in mind and reported when they occur. One would like to make a plea, therefore, that this should be done.

It is possible that the relatively large number of cases of neurological complications of pertussis immunization reported from the United States, as opposed to other countries, including Britain, is due to a greater awareness of, and interest in, the problem in America. If further cases are reported, as Drs. Thursby-Pelham and Giles have now done, it may be that the commonly held view, that the dangers from whooping-cough itself are much greater than those from immunizing against it, will require modification.—I am, etc.,

London, S.W.17.

J. M. BERG.

SIR,—Further to the article by Dr. J. M. Berg (*Journal*, July 5, p. 24) and the letter from Dr. D. C. Thursby-Pelham and Dr. C. Giles (*Journal*, July 26, p. 246), I have given many thousands of injections of both combined diphtheria-pertussis and triple antigen vaccines, and in two instances only have I known convulsions to follow, in sisters.

*Case No. 1.*—A female infant, first child of a Rhesus-negative mother. Became jaundiced three days after birth. Was admitted to hospital but replacement transfusion unnecessary. At 6 months of age she had a severe convulsion which occurred four hours after her first injection of triple antigen. She was un-

on those who seek his advice about their treatment. Logically a doctor could only advise a patient to take such an unknown substance if there was no accredited or orthodox treatment for the condition from which he was suffering. The medicaments prescribed by a general practitioner should be those which he uses in good faith and on the basis of knowledge which he has obtained of their composition and action from different sources. Where the progress of a disease invariably follows a predictable and well-established course, then the past experience of accumulated medical knowledge supplies the control for any therapeutic trial of a possibly beneficial drug, and no other may be needed. The most obvious examples are those diseases in which death is the invariable or predictable result. If, on the grounds of a reasonable hypothesis, the first therapeutic trial of a new substance for the treatment of such a disease were being planned—for example, streptomycin in tuberculous meningitis—it could be argued that it would be unethical to withhold this test substance from any patient in the trial. A proper structure of this first trial might well be to test the action of the new substance in a continuous series of cases until the question was beyond doubt, either that it had no action or that the predictable course of the disease was undoubtedly altered by the use of the test substance. In general practice, however, such trials are rare.

Therapeutic research in general practice falls broadly into six categories. The first, and perhaps a neglected field, is a fresh assessment of the action of time-honoured remedies in common diseases—for example, the use of potassium iodide or tincture of stramonium in asthma. Second comes the controlled trial of new drugs for old and familiar diseases, such as the prophylactic use of sulphonamides for the complications of measles. Third come trials designed to reveal new uses of familiar drugs, such as aspirin in diabetes. Fourth, and we hope rarely in general practice, comes the administration of new and unfamiliar drugs to patients with diseases for which a standard treatment already exists. The fifth comprises those trials where the family doctor is in ignorance of the precise nature of the

We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and analytics partners.

[Our privacy and cookie policy](#) [Show Vendors](#)

[Cookie Settings](#)

[Accept Cookies](#)

### Neurological Complications of Pertussis Immunization

SIR.—Drs. D. C. Thursby-Pelham and C. Giles's letter (*Journal*, July 26, p. 246) is of great interest. It is remarkable that Dr. Thursby-Pelham has seen six patients in the space of 10 years with neurological reactions following pertussis immunization, in view of the fact that only seven such cases have been recorded in Great Britain (see my paper, *Journal*, July 5, p. 24). One of these seven is Case 2 in their series. It may be, as Drs. Thursby-Pelham and Giles state, that the dangers of whooping-cough immunization are greater than is commonly thought, but this can only be established if the possibility of reactions to immunization are borne in mind and reported when they occur. One would like to make a plea, therefore, that this should be done.

It is possible that the relatively large number of cases of neurological complications of pertussis immunization reported from the United States, as opposed to other countries, including Britain, is due to a greater awareness of, and interest in, the problem in America. If further cases are reported, as Drs. Thursby-Pelham and Giles have now done, it may be that the commonly held view, that the dangers from whooping-cough itself are much greater than those from immunizing against it, will require modification.—I am, etc.,

London, S.W.17.

J. M. BERG.

SIR.—Further to the article by Dr. J. M. Berg (*Journal*, July 5, p. 24) and the letter from Dr. D. C. Thursby-Pelham and Dr. C. Giles (*Journal*, July 26, p. 246), I have given many thousands of injections of both combined diphtheria-pertussis and triple antigen vaccines, and in two instances only have I known convulsions to follow, in sisters.

*Case No. 1.*—A female infant, first child of a Rhesus-negative mother. Became jaundiced three days after birth. Was admitted to hospital but replacement transfusion unnecessary. At 6 months of age she had a severe convulsion which occurred four hours after her first injection of triple antigen. She was un-

on those who seek his advice about their treatment. Logically a doctor could only advise a patient to take such an unknown substance if there was no accredited or orthodox treatment for the condition from which he was suffering. The medicaments prescribed by a general practitioner should be those which he uses in good faith and on the basis of knowledge which he has obtained of their composition and action from different sources. Where the progress of a disease invariably follows a predictable and well-established course, then the past experience of accumulated medical knowledge supplies the control for any therapeutic trial of a possibly beneficial drug, and no other may be needed. The most obvious examples are those diseases in which death is the invariable or predictable result. If, on the grounds of a reasonable hypothesis, the first therapeutic trial of a new substance for the treatment of such a disease were being planned—for example, streptomycin in tuberculous meningitis—it could be argued that it would be unethical to withhold this test substance from any patient in the trial. A proper structure of this first trial might well be to test the action of the new substance in a continuous series of cases until the question was beyond doubt, either that it had no action or that the predictable course of the disease was undoubtedly altered by the use of the test substance. In general practice, however, such trials are rare.

Therapeutic research in general practice falls broadly into six categories. The first, and perhaps a neglected field, is a fresh assessment of the action of time-honoured remedies in common diseases—for example, the use of potassium iodide or tincture of stramonium in asthma. Second comes the controlled trial of new drugs for old and familiar diseases, such as the prophylactic use of sulphonamides for the complications of measles. Third come trials designed to reveal new uses of familiar drugs, such as aspirin in diabetes. Fourth, and we hope rarely in general practice, comes the administration of new and unfamiliar drugs to patients with diseases for which a standard treatment already exists. The fifth comprises those trials where the family doctor is in ignorance of the precise nature of the

- [UK jobs](#)

We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and analytics partners.

[Our privacy and cookie policy](#) [Show Vendors](#)

[› Cookie Settings](#)

[✓ Accept Cookies](#)



[View more](#)

 Check for updates

Royal Medico-Psychological Association.  
**Neurological Complications of Pertussis Immunization**

SIR.—Drs. D. C. Thursby-Pelham and C. Giles's letter (*Journal*, July 26, p. 246) is of great interest. It is remarkable that Dr. Thursby-Pelham has seen six patients in the space of 10 years with neurological reactions following pertussis immunization, in view of the fact that only seven such cases have been recorded in Great Britain (see my paper, *Journal*, July 5, p. 24). One of these seven is Case 2 in their series. It may be, as Drs. Thursby-Pelham and Giles state, that the dangers of whooping-cough immunization are greater than is commonly thought, but this can only be established if the possibility of reactions to immunization are borne in mind and reported when they occur. One would like to make a plea, therefore, that this should be done.

It is possible that the relatively large number of cases of neurological complications of pertussis immunization reported from the United States, as opposed to other countries, including Britain, is due to a greater awareness of, and interest in, the problem in America. If further cases are reported, as Drs. Thursby-Pelham and Giles have now done, it may be that the commonly held view, that the dangers from whooping-cough itself are much greater than those from immunizing against it, will require modification.—I am, etc.,

London, S.W.17.

J. M. BERG.

SIR.—Further to the article by Dr. J. M. Berg (*Journal*, July 5, p. 24) and the letter from Dr. D. C. Thursby-Pelham and Dr. C. Giles (*Journal*, July 26, p. 246), I have given many thousands of injections of both combined diphtheria-pertussis and triple antigen vaccines, and in two instances only have I known convulsions to follow, in sisters.

*Case No. 1.*—A female infant, first child of a Rhesus-negative mother. Became jaundiced three days after birth. Was admitted to hospital but replacement transfusion unnecessary. At 6 months of age she had a severe convulsion which occurred four hours after her first injection of triple antigen. She was un-

on those who seek his advice about their treatment. Logically a doctor could only advise a patient to take such an unknown substance if there was no accredited or orthodox treatment for the condition from which he was suffering. The medicaments prescribed by a general practitioner should be those which he uses in good faith and on the basis of knowledge which he has obtained of their composition and action from different sources. Where the progress of a disease invariably follows a predictable and well-established course, then the past experience of accumulated medical knowledge supplies the control for any therapeutic trial of a possibly beneficial drug, and no other may be needed. The most obvious examples are those diseases in which death is the invariable or predictable result. If, on the grounds of a reasonable hypothesis, the first therapeutic trial of a new substance for the treatment of such a disease were being planned—for example, streptomycin in tuberculous meningitis—it could be argued that it would be unethical to withhold this test substance from any patient in the trial. A proper structure of this first trial might well be to test the action of the new substance in a continuous series of cases until the question was beyond doubt, either that it had no action or that the predictable course of the disease was undoubtedly altered by the use of the test substance. In general practice, however, such trials are rare.

Therapeutic research in general practice falls broadly into six categories. The first, and perhaps a neglected field, is a fresh assessment of the action of time-honoured remedies in common diseases—for example, the use of potassium iodide or tincture of stramonium in asthma. Second comes the controlled trial of new drugs for old and familiar diseases, such as the prophylactic use of sulphonamides for the complications of measles. Third come trials designed to reveal new uses of familiar drugs, such as aspirin in diabetes. Fourth, and we hope rarely in general practice, comes the administration of new and unfamiliar drugs to patients with diseases for which a standard treatment already exists. The fifth comprises those trials where the family doctor is in ignorance of the precise nature of the

## This week's poll

Should medical schools relax academic a

- Yes
- No

Vote

[View Results](#)

[Read](#) related article

[See](#) previous polls

We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and analytics partners. Our privacy and cookie policy [Show Vendors](#)

[Cookie Settings](#)

[Accept Cookies](#)